XVIE for Male Pattern Baldness

This clinical trial explores a new injectable treatment, called XVIE, which might help regrow hair in individuals with androgenetic alopecia, commonly known as male pattern baldness. The primary goal is to ensure the safety of XVIE, made from processed human amniotic fluid, which may stimulate hair growth. Participants will receive either the treatment or a placebo (an inactive substance) to compare results over six months. The trial seeks individuals with documented hair loss and a stable pattern of hair loss for at least six months, without recent use of certain hair loss treatments. As a Phase 1, Phase 2 trial, this research focuses on understanding how the treatment works in people and measuring its effectiveness in an initial, smaller group.

You may need to stop certain medications before joining the trial. Specifically, you cannot use minoxidil, finasteride, or certain other hair treatments for a few months before starting. Check with the study team about your specific medications.

Research shows that XVIE, a new treatment being tested for hair loss, is under study to assess its safety and effectiveness. Made from processed human amniotic fluid, XVIE includes growth factors and tiny particles that might promote hair growth.

Although specific safety data from past studies is not available, the FDA has accepted an application to study XVIE, suggesting some confidence in its potential safety. The treatment remains in the early stages of research, focusing primarily on ensuring safety for participants. While the treatment appears promising, unknown side effects may still exist.

Unlike the standard treatments for male pattern baldness, which typically include topical minoxidil and oral finasteride, XVIE is derived from decellularized allogeneic human amniotic fluid. This novel treatment is administered via intradermal scalp injections, offering a different delivery method that directly targets the hair follicles. Researchers are excited because XVIE's unique composition could promote hair regrowth by leveraging growth factors and proteins found in amniotic fluid, potentially offering a new pathway to stimulate hair growth where other treatments primarily focus on hormonal pathways or blood flow enhancement.

Research has shown that XVIE, derived from processed human amniotic fluid, contains substances that may stimulate hair growth. This trial will compare the effects of XVIE with a placebo to evaluate its potential for hair regrowth in individuals with male pattern baldness. Early results suggest that products like XVIE may promote hair growth. Although studies are ongoing, the use of amniotic fluid to support hair growth makes XVIE an intriguing option for those experiencing hair loss.¹²³⁴⁶